D. Stolz (Basel, Switzerland), G. Rohde (Bochum, Germany)
Management and outcomes of lower respiratory tract infection in UK primary care
C. Winchester, T. Macfarlane, M. Thomas, D. Price (Aberdeen, United Kingdom)
|   |
Patients‘ characteristics do not influence duration of antibiotic therapy (ABT) in hospitalized patients with community-acquired pneumonia (CAP): results from the CAPO international study
S. Aliberti, P. Peyrani, F. Blasi, P. Tarsia, L. Allegra, J. Ramirez (Milan, Italy; Louisville, KY, United States Of America)
| |
Evaluation of severity, inflammatory response and adherence to treatment guidelines impact on community-acquired pneumonia outcomes
V. Dudzevicius, N. Ghazal, R. Ineson, S. Muzaffar, G. Antunes, N. Krishnaraj, S. Murphy (Middlesbrough, United Kingdom)
| |
Community-acquired pneumonia in alcohol abuse patients
A. Cervera, E. Fernández-Fabrellas, J. Blanquer, M. L. Briones, F. Sanz, C. Senent, E. Chiner, M. C. Aguar (Valencia, Spain)
| |
Site of care for community-acquired pneumonia (CAP) patients with CRB-65 score of 0-1 and pneumonia severity index (PSI) risk class (RC) of IV-V: what to do when this discrepancy occurs. Results from the CAPO international study
P. F. Castellotti, V. Rossetti, S. Aliberti, P. Tarsia, P. Peyrani, F. Blasi, J. Ramirez (Milan, Italy; Louisville, KY, United States Of America)
| |
Can improved outcomes be achieved when patients with community acquired pneumonia are managed in accordance with the national guidelines?
R. Parthasarathy, C. Cannon, V. Williams (Grimsby, Swindon, United Kingdom)
| |
Clinical characteristics and symptoms in older and younger patients with community acquired pneumonia
S. Krueger, C. Schumann, R. Marre, N. Suttorp, T. Welte (Aachen, Ulm, Berlin, Hannover, Germany)
| |
Pro-atrial natriuretic peptide to predict short-term and long-term mortality in community-acquired pneumonia
S. Krueger, J. Kunde, A. Hanschmann, R. Marre, N. Suttorp, T. Welte (Aachen, Hennigsdorf, Ulm, Berlin, Hannover, Germany)
| |
Plasma fibrinogen concentration is an independent marker of severity in patients with community acquired pneumonia
J. Chalmers, A. Singanayagam, M. Murray, A. Hill (Edinburgh, United Kingdom)
| |
Severity of illness score in patients with bacteremic pneumococcal pneumonia: implications for ICU care
C. Feldman, S. Alanee, V. Yu, G. Richards, A. Ortqvist, J. Rello, C. Chiou, M. Wagener, K. Klugman (Pittsburgh, PA, United States Of America; Johannesburg, South Africa; Stockholm, Sweden; Tarragona, Spain)
| |
CURB-65 score is related to length of stay in community-acquired pneumonia
D. Snijders, C. de Graaff, W. Boersma (Alkmaar, Netherlands)
| |
Risk factors of treatment failure of community acquired pneumonia in patients with COPD
U. Sohta, M. Kato, C. Yonemoto, Y. Koshimo, N. Tanabe, K. Miura, S. Goto, M. Kawashima (Kishiwada/Osaka, Japan)
| |
Acute myocardial infarction in hospitalized patients with community-acquired pneumonia: results from the CAPO international cohort study
J. Ramirez, S. Aliberti, M. Mirsaeidi, P. Peyrani, G. Filardo, G. Levy, P. Fernandez, D. Legnani, M. Mateo, M. Bodi, J. Martinez, F. Blasi, The CAPO Investigators (Louisville, KY, Dallas, TX, United States Of America; Milan, Italy; Caracas, Venezuela; Sa
| |
Female gender is associated with poor clinical outcomes in hospitalized patients with community-acquired pneumonia: results from the CAPO international cohort study
M. Mirsaeidi, P. Peyrani, J. Portillo, M. Allen, F. Arteta, J. Porras, J. Roig, E. Rodriguez, M. Rodriguez, J. Ramirez, The CAPO Investigators (Louisville, KY, United States Of America; Barquisimeto, Venezuela; Tarragona, Spain; Escaldes, Andorra; La Pla
| |
Tigecycline vs levofloxacin for the treatment of community-acquired pneumonia (CAP): EU experience
N. Dartois, N. Castaing, H. Gandjini, G. Dukart, A. Cooper (Paris, France; Collegeville, PA, United States Of America)
| |
A worldwide perspective of the level of compliance with guidelines in hospitalized patients with community-acquired pneumonia: results from the CAPO cohort international study
P. Peyrani, J. Rello, R. Menendez, P. Rossi, A. Torres, F. Blasi, R. Cosentini, C. Luna, C. Feldman, J. Ramirez, The CAPO Investigators (Louisville, KY, United States Of America; Tarragona, Valencia, Barcelona, Spain; Udine, Milan, Italy; Buenos Aires, A
| |
Impact of host status, bacteria and antibiotic therapy on systemic inflammatory response syndrome (SIRS) development in community-acquired pneumonia (CAP)
F. Sanz, J. Blanquer, E. Fernández, A. Cervera, C. Aguar, E. Chiner, R. Blanquer (Valencia, Spain)
| |
Fluoroquinolone versus β-lactam plus macrolide in patients hospitalized with community-acquired pneumonia (CAP)
M. Volpi, S. Aliberti, A. M. Brambilla, R. Cosentini, A. Torri, F. Blasi (Milan, Italy)
| |
The effect of educational interventions of administering the first dose of antibiotics within 4 hours on community acquired pneumonia management
J. H. Chung, C. J. Kim, S. M. Lee, C. H. Han (Koyang, Republic Of Korea)
| |
Reasons that justify hospitalization for community-acquired pneumonia (CAP) patients with CURB-65 score 0-1
S. Aliberti, P. F. Castellotti, A. M. Brambilla, R. Cosentini, V. Rossetti, F. Tantardini, P. Tarsia, P. Peyrani, J. Ramirez, F. Blasi (Milan, Italy; Louisville, KY, United States Of America)
| |